Shares of famous Danish weight-drug loss producer Novo Nordisk (NOVOB.DK) are reaching now all-time highs above 1000 DKK as Wegovy weight-loss treatment received approval from regulators in China.
- Novo Nordisk didn't comment when exactly it will be selling its products on Chinese market. Supply nor Wegovy prices on Chinese market are not known. According to a Chinese public health study, number of overweight adults in China can reach 540 million by 2030 rising 280% since 2000 level.
- Novo Nordisk is currently the highest valued, European company and year-to-date Novo risen almost 45%. Yesterday, on Monday 24 June, the company announced $4.1 facility investment in the North Carolina (US), to boost its manufacturing capabilities.
Novo Nordisk (NOVOB.DK, D1 interval)
During last 12 months the most important support zone for Novo Nordisk was near SMA50 (orange line) and in correction scenario levels near 900-920DKK may be important.
Source: xStation5
🗽 شركات مؤشر ستاندرد آند بورز 500 التي حققت أعلى هامش ربح صافٍ منذ عام 2009 - بيانات فاكت سيت
ملخص السوق: مؤشر UK100 يرتفع بشكل صاروخي بعد تصريح بنك إنجلترا 🚀 مكاسب هائلة بعد خطاب لاغارد من البنك المركزي الأوروبي 📈
نتائج أبل للربع الثاني من عام 2026: نتائج مستقرة أم بداية دورة نمو جديدة؟
حصاد الأسواق: نتائج قياسية لشركات التكنولوجيا الكبرى مدفوعة بالذكاء الاصطناعي، والاحتياطي الفيدرالي لا يُقدم مفاجآت
